Bergsneider Marvin, Mirsadraei Leili, Yong William H, Salamon Noriko, Linetsky Michael, Wang Marilene B, McArthur David L, Heaney Anthony P
Department of Neurosurgery, David Geffen School of Medicine at UCLA, Gonda 3357, BOX 951761, Los Angeles, CA, 90095-1761, USA,
J Neurooncol. 2014 May;117(3):477-84. doi: 10.1007/s11060-014-1386-5. Epub 2014 Feb 19.
Most patients with large pituitary tumors do not exhibit hyperprolactinemia as a result of pituitary lactotroph disinhibition (stalk effect). Studies have demonstrated that increased intrasellar pressure is associated with both "stalk effect" hyperprolactinemia and pituitary insufficiency. Our primary hypothesis was that, despite continued disinhibition, lactotroph failure is responsible for normoprolactinemia in patients with large macroadenomas. As a corollary, we proposed that the hyperprolactinemia phase, which presumably would precede the insufficiency/normoprolactinemic state, would more likely be discovered in premenopausal females and go unnoticed in males. Prospective, consecutive surgical series of 98 patients of clinically nonfunctional pituitary adenomas. Lactotroph insufficiency was inferred by the coexistence of insufficiency in another pituitary axis. The existence of pre-operative lactotroph disinhibition was inferred based on comparison of pre- versus post-operative prolactin levels. 87 % of patients with tumor size >20 mm and normoprolactinemia had pituitary insufficiency. Pre-operative prolactin in patients with pituitary insufficiency were lower than those with intact pituitary function. Prolactin levels dropped in nearly all patients, including patients with normoprolactinemia pre-operatively. Premenopausal women had smaller tumors and higher pre-operative prolactin levels compared to males. No premenopausal female exhibited evidence of pituitary insufficiency. Our study provides suggestive evidence that the "stalk effect" pathophysiology is the norm rather than the exception, and that the finding of normoprolactinemia in a patient with a large macroadenoma is likely a consequence of lactotroph insufficiency. In males, the hyperprolactinemia window is more likely to be missed clinically due to an absence of prolactin-related symptoms.
大多数患有大型垂体瘤的患者不会因垂体催乳素细胞去抑制(垂体柄效应)而出现高催乳素血症。研究表明,鞍内压力升高与“垂体柄效应”高催乳素血症和垂体功能不全均有关。我们的主要假设是,尽管存在持续的去抑制,但催乳素细胞功能衰竭是导致大型大腺瘤患者催乳素水平正常的原因。作为一个推论,我们提出,高催乳素血症阶段可能先于垂体功能不全/催乳素水平正常状态出现,在绝经前女性中更有可能被发现,而在男性中则可能未被注意到。对98例临床无功能垂体腺瘤患者进行前瞻性、连续性手术系列研究。通过另一垂体轴功能不全的共存来推断催乳素细胞功能不全。根据术前与术后催乳素水平的比较推断术前催乳素细胞去抑制的存在。肿瘤大小>20mm且催乳素水平正常的患者中,87%存在垂体功能不全。垂体功能不全患者的术前催乳素水平低于垂体功能正常的患者。几乎所有患者的催乳素水平都下降了,包括术前催乳素水平正常的患者。与男性相比,绝经前女性的肿瘤较小,术前催乳素水平较高。没有绝经前女性表现出垂体功能不全的证据。我们的研究提供了提示性证据,表明“垂体柄效应”病理生理学是常态而非例外,并且在大型大腺瘤患者中发现催乳素水平正常可能是催乳素细胞功能不全的结果。在男性中,由于缺乏与催乳素相关的症状,临床上更有可能错过高催乳素血症阶段。